

BMJ Open Prognostic value of miR-219-5p in relation to mortality in patients with small cell lung cancer: a retrospective, observational cohort study in China

Xiangmei Wu,¹ Jigang Zhang,² Xiaohui Zhang,³ Mengqi Xiang,⁴ Zhihua Xu ,⁵ Zhijun Cao⁶

To cite: Wu X, Zhang J, Zhang X, *et al.* Prognostic value of miR-219-5p in relation to mortality in patients with small cell lung cancer: a retrospective, observational cohort study in China. *BMJ Open* 2023;**13**:e064700. doi:10.1136/bmjopen-2022-064700

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-064700>).

2

XW, JZ and XZ contributed equally.

Received 13 May 2022
Accepted 24 February 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Zhijun Cao;
360596357@qq.com and
Dr Zhihua Xu;
dr_zhihuaxu@163.com

ABSTRACT

Objectives Small cell lung cancer (SCLC) is a lethal human malignancy, and previous studies support the contribution of microRNA to cancer progression. The prognostic value of miR-219-5p in patients with SCLC remains unclear. This study aimed to evaluate the predictive value of miR-219-5p with respect to mortality in patients with SCLC and to incorporate miR-219-5p level into a prediction model and nomogram for mortality.

Design Retrospective observational cohort study.

Setting and participants Our main cohort included data from 133 patients with SCLC between 1 March 2010 and 1 June 2015 from the Suzhou Xiangcheng People's Hospital. Data from 86 patients with non-SCLC at Sichuan Cancer Hospital and the First Affiliated Hospital of Soochow University were used for external validation.

Outcome measures Tissue samples were taken during admission and stored, and miR-219-5p levels were measured at a later date. A Cox proportional hazard model was used for survival analyses and for analysing risk factors to create a nomogram for mortality prediction. The accuracy of the model was evaluated by C-index and calibration curve.

Results Mortality in patients with a high level of miR-219-5p (≥ 1.50) ($n=67$) was 74.6%, while mortality in the low-level group ($n=66$) was 100.0%. Based on univariate analysis, we included significant factors ($p<0.05$) in a multivariate regression model: patients with high level of miR-219-5p (HR 0.39, 95% CI 0.26–0.59, $p<0.001$), immunotherapy (HR 0.44, 95% CI 0.23–0.84, $p<0.001$) and prognostic nutritional index score >47.9 (HR=0.45, 95% CI 0.24–0.83, $p=0.01$) remained statistically significant factors for improved overall survival. The nomogram had good accuracy in estimating the risk, with a bootstrap-corrected C-index of 0.691. External validation indicated an area under the curve of 0.749 (0.709–0.788).

Conclusions The miR-219-5p level was associated with a reduced risk of mortality in patients with SCLC. A nomogram incorporating miR-219-5p level and clinical factors demonstrated good accuracy in estimating the risk of overall mortality. Prospective validation of the prognostic nomogram is needed.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ The study uses databases of all patients with small cell lung cancer (SCLC) in two defined geographical regions of China.
- ⇒ The study included the creation of a nomogram for predicting survival probabilities in individual patients.
- ⇒ However, the model is not comprehensive since the database does not include all prognostic factors for SCLC.
- ⇒ Additionally, the available data on treatment status are not adequately detailed to distinguish the impact of various treatment plans.
- ⇒ The model needs to be prospectively assessed to determine its reliability.

INTRODUCTION

Lung cancer is the leading cause of cancer deaths worldwide, with millions of new cases diagnosed each year.¹ Small cell lung cancer (SCLC) is a kind of neuroendocrine malignant tumour with poor prognosis, accounting for about 15% of patients with lung cancer.² SCLC is generally divided into limited disease (LD-SCLC) and extensive disease (ED-SCLC). A combination of platinum and etoposide regimen is the first-line therapeutic strategy for SCLC, and most patients are easy to receive initial chemotherapy.³ However, the 5-year survival rates of LD-SCLC and ED-SCLC are only 15% and 3%, respectively.⁴ Therefore, improvement in early diagnosis and prognostic prediction of SCLC is vital.

MicroRNAs (miRNAs) are endogenous non-coding RNAs (~22 nt), which regulate mRNA activity by hybridisation with 3'-untranslated region of specific genes.⁵ Many studies have shown that miRNAs could have a role in a variety of cell biological processes, including cell growth, differentiation and apoptosis.^{6,7} In addition, researches have demonstrated that miRNAs are

frequently dysregulated in cancers,^{8,9} and some miRNAs can serve as diagnostic and prognostic biomarkers for cancers.¹⁰ Recently, several miRNAs have been proven to have a role in the occurrence and development of SCLC, but few of them are likely to be a biomarker or therapeutic target for SCLC.

Recently, miR-219-5p has been found to be abnormally expressed and play a significant role in different cancers. Ma found that the expression of miR-219-5p was significantly decreased in oesophageal squamous cell carcinoma tissues compared with normal tissues.¹¹ A study by Gong *et al* revealed a tumour suppressive role of miR-219-5p by targeting glypican-3 in hepatocellular carcinoma (HCC).¹² On the contrary, Yang *et al* indicated that miR-219-5p could promote cell growth and metastasis of HCC and serve as a prognostic marker for patients with HCC.¹³ A research investigated by Wei *et al* suggested that miR-219-5p could inhibit proliferation, migration and invasion of epithelial ovarian cancer through downregulation of the Wnt signalling pathway, and it could serve as a diagnostic biomarker and therapeutic target for epithelial ovarian cancer.¹⁴ However, the biological functions of miR-219-5p and its potential prognostic role as a biomarker in SCLC are still unknown.

In this study, we aimed to examine the variation in the expression levels of miR-219-5p in patients with SCLC, to evaluate the predictive value of miR-219-5p with respect to mortality in patients with SCLC, and to incorporate miR-219-5p level into a prediction model and nomogram for mortality.

METHODS

Study design and patients

The study uses databases of all patients with SCLC in two defined geographical regions of China. Our main cohort included data obtained from 133 patients with SCLC between March 2010 and June 2015, in the Suzhou Xiangcheng People's Hospital. Tissue samples were taken during admission and stored, and the miR-219-5p levels were measured at a later date. Those participants who lacked information on complement components data, withdrew from treatment or lacked follow-up information were excluded. Clinical information of patients, including gender, age, body mass index, neutrophil count, lymphocyte count, serum carcinoembryonic antigen (CEA) level, C reactive protein (CRP) level, albumin level, haemoglobin level, stage of SCLC, platelet count, prognostic nutritional index (PNI) score, Karnofsky Performance Status (KPS) score, neutrophil-lymphocyte ratio, pathological type, immunotherapy, radiation therapy, use of platinum, use of vascular endothelial growth factor inhibitor, target therapy, use of tyrosine kinase inhibitor (TKI), smoking, acute coronary syndrome (ACS), diabetes, heart failure and hyperlipaemia, were recorded. Diagnosis of SCLC was confirmed by histopathological examination. The median length of follow-up was 23.6 months. Median was used as the cut-off value. The definition and

details of all the variables above were provided in online supplemental material part I. Data from 86 patients with non-SCLC (NSCLC) at Sichuan Cancer Hospital and the First Affiliated Hospital of Soochow University were used for external validation.

Assays for detection of miR-219-5p levels

The quantitative reverse transcription-PCR (qRT-PCR) was conducted for the detection of miR-219-5p expression levels.

Total RNA from tissues was isolated and extracted using miRcute Extraction and Separation of miRNAs kit (Tiangen Biotech Co, Beijing, China), and then reversely transcribed into cDNA by PrimeScript II 1st strand cDNA synthesis kit (Takara Biotechnology Co, Dalian, China) according to the manufacturer's protocol. SYBR PrimeScript miRNA RT-PCR kit (Takara Biotechnology Co) was used for qRT-PCR. The thermocycling conditions were as follows: one cycle at 95°C for 3 min (initial denaturation), 40 cycles at 95°C for 15 s and 60°C for 30 s. U6 small nuclear RNA (U6) served as the respective internal control. The relative expression of miR-219-5p was quantified by the $2^{-\Delta\Delta Ct}$ methods and normalised to the U6. The following primers were used: miR-219-5p forward, 5'-ACACTCCAGCTGGGTGATTGTCCAAACGCAAT-3' and reverse, 5'-CTCAACTGGTGTCTGGA-3'; U6 forward, 5'-GCTTCGGCAGCACATATACTAAAAT-3' and reverse, 5'-CGCTTACGAATTTGCGTGTTCAT-3'. The experiments were repeated at least three times.

Statistical analysis

Sample size assessment was performed using NCSS-PASS software V.11.0 (<https://www.ncss.com/software/pass/>). Power was set as 0.99, and α was set as 0.5. The mortality data in both the groups with high-level miR-219-5p and low-level miR-219-5p in our previous data (2008–2009) (0.750 and 0.950) were entered into the PASS. The actual HR was set as 0.50. Then, the sample size was calculated using PASS, and the minimum sample size was 94 (control=51, experiment=43). Our sample size was 133 (66 and 67, respectively, for each group), which was suitable. The report of sample size assessment was displayed in online supplemental material part II. The missing data (<5.0%) were estimated by random forest algorithm using the mice package in RStudio (R V.3.6.1). Categorical variables were presented as percentages and compared via the κ^2 test. Continuous variables with skewed and normal distributions were presented as median with IQRs and mean \pm SD. The Mann-Whitney U test and the unpaired t-test were applied for comparison between groups. Cumulative mortality was shown by the Kaplan-Meier curve and analysed by the log-rank test. Univariate and multivariate survival analyses for overall survival (OS) were conducted using the Cox regression model. The forest plots were used to visualise the significance of covariates to the prognosis. The restricted cubic spline analyses were performed with Harrell's Regression Modelling Strategies (rms) package.

We screened multifactor analysis for statistically significant indicators for inclusion in the prediction model. To build the nomogram, we found the position of each variable on the corresponding axis, drew a line to the points axis for the number of points, added the points from all the variables and drew a line from the total points axis to determine the OS probabilities at the lower line of the nomogram. The contribution of each covariate was quantified and visualised in a prognostic nomogram with internal validation via 1000-time bootstrapping. The consistency of the resulting model was assessed by the calibration assay. Decision curve analyses were performed to evaluate net clinical benefits of the model compared with conventional prognostic scores. The scatter plots were applied for visualisation of the consistency of each model. A 1000-time bootstrapping was employed as indicated. The association between miR-219-5p class and survival endpoints was evaluated by Kaplan-Meier curves and log-rank test. Statistical analysis was performed using the RStudio (R V.3.6.1) with the following packages: ‘ggplot2’, ‘rms’, ‘PredictABLE’, ‘risk regression’ and ‘survminer’.

Patient and public involvement

None.

RESULTS

Baseline characteristics

A total of 133 patients with SCLC who were diagnosed between March 2010 and June 2015 were included in the main cohort. A flow chart of the screening process




Figure 1 Study screening flow chart. SCLC, small cell lung cancer; SLE, systemic lupus erythematosus.

was shown in [figure 1](#). The median age of these patients was 64 years old (58–70 years), and 106 (80.0%) were male. Median serum CEA and CRP level was 3.43 ng/mL and 7.83 μ mol/L, respectively. For the stage of SCLC, 51 (38.0%) patients were diagnosed with LD-SCLC, while 82 (61.0%) patients were diagnosed with ED-SCLC. Twenty-five (19.0%) patients accepted the immunotherapy, while 54 (41.0%) patients got the radiation therapy. In addition, platinum was used for 131 (98.0%) patients, and TKI was used for 15 (12.0%) patients. The KPS score of these patients was examined, and the results revealed that 107 (81.0%) patients got 80 or higher points. The distribution of basic diseases was also assessed in our data. Diabetes was found in 17 (13.0%) patients, and hyperlipaemia in 13 (10.0%) patients. Cardiovascular diseases such as heart failure and ACS were found in three (2.0%) and four (3.0%) patients, respectively. Thirteen (10.0%) patients suffered from hypertension. In addition, 82 (62.0%) patients had a habit of smoking. The baseline characteristics of these patients were listed in [table 1](#).

Among all the 133 patients, overall mortality was 87.2%. The mortality in the group with high-level miR-219-5p (n=67) was 74.6%, while the mortality in the low-level group (n=66) was 100.0%. Moreover, in the group with high-level miR-219-5p, there were 35 (52.0%) patients with ED-SCLC, while in the low-level group, there were 47 (71.0%) ([table 1](#)).

miR-219-5p expression level and clinical risk factors

According to the univariate analysis, having high levels of miR-219-5p (≥ 1.50) was a strong protective predictor of mortality (HR 0.36, 95% CI 0.25–0.53, $p < 0.001$) ([table 2](#)). The Kaplan-Meier curve showed that patients in the group with high levels of miR-219-5p had a decreased cumulative rate of death compared with those in the group with low levels of miR-219-5p (log-rank $p < 0.001$) ([figure 2A](#)). Meanwhile, patients who accepted immunotherapy also showed a low mortality compared with those patients not accepting immunotherapy, as shown in the survival curve (HR 0.28, 95% CI 0.15–0.52, $p < 0.001$) ([figure 2B](#)).

In addition, gender, age, serum CRP level, albumin level, lymphocyte count, PNI score, immunotherapy, heart failure and KPS score were also correlated with overall mortality ([table 2](#)). When adjusted by age and gender, patients in the group with high-level miR-219-5p also displayed a low cumulative rate of death compared with those in the low-level group.

Independent prognostic factors for OS

After the multivariate adjustment, having a high level of miR-219-5p (HR 0.39, 95% CI 0.26–0.59, $p < 0.001$) was also associated with a low increase in the risk of death ([figure 3](#)). Meanwhile, gender, PNI score, immunotherapy and heart failure were also the independent risk factors for OS.

Table 1 Study participant characteristics at enrolment

Variation	Total (n=133)	Cohort, median (IQR)		P value
		miR-219-5p <1.50 (n=66)	miR-219-5p ≥1.50 (n=67)	
Age (years)	64 (58–70)	65 (59–70)	63 (56.5–68)	0.276
BMI (kg/m ²)	23.12±3.09	22.99±3.22	23.26±2.98	0.619
Serum CEA level (ng/mL)	3.43 (1.96–9.26)	3.34 (1.92–10.05)	3.43 (1.99–8.11)	0.87
Serum CRP level (µmol/L)	7.83 (1.68–12.78)	10.68 (2.78–13.15)	5.64 (1.2–12.16)	0.107
Albumin level (g/L)	39.46±5.2	38.86±4.68	40.05±5.65	0.188
Neutrophil count (×10 ⁹ /L)	4.55 (3.59–5.88)	4.54 (3.77–5.75)	4.55 (3.48–5.92)	0.975
Lymphocyte count (×10 ⁹ /L)	1.63 (1.31–1.95)	1.5 (1.21–1.78)	1.73 (1.38–2.08)	0.031*
Haemoglobin level (g/L)	133 (125–145)	134 (124–145)	132 (125–143.5)	0.564
Platelet count (×10 ⁹ /L)	233 (184–288)	244.5 (180–293.75)	226 (184.5–273.5)	0.306
PNI score	47.9 (43.95–51.85)	45.98 (42.51–50.38)	48.7 (44.92–54)	0.026*
NLR	2.66 (1.99–4.19)	2.75 (2.11–4.57)	2.59 (1.92–3.7)	0.232
Gender, n (%)				0.211
Female	27 (20)	10 (15)	17 (25)	
Male	106 (80)	56 (85)	50 (75)	
Metastasis, n (%)				0.299
No	45 (34)	19 (29)	26 (39)	
Yes	88 (66)	47 (71)	41 (61)	
Stage of SCLC				0.038*
Limited disease	51 (38)	19 (29)	32 (48)	
Extensive disease	82 (62)	47 (71)	35 (52)	
Immunotherapy, n (%)				0.197
No	108 (81)	57 (86)	51 (76)	
Yes	25 (19)	9 (14)	16 (24)	
Radiation therapy, n (%)				0.417
No	79 (59)	42 (64)	37 (55)	
Yes	54 (41)	24 (36)	30 (45)	
Use of platinum, n (%)				0.244
No	2 (2)	2 (3)	0 (0)	
Yes	131 (98)	64 (97)	67 (100)	
Chemotherapy				0.45
AP	28 (21)	12 (18)	16 (24)	
DP	15 (11)	6 (9)	9 (13)	
EP	71 (53)	35 (53)	36 (54)	
GP	3 (2)	2 (3)	1 (1)	
Others	16 (12)	11 (17)	5 (7)	
Target therapy, n (%)				0.627
No	116 (87)	59 (89)	57 (85)	
Yes	17 (13)	7 (11)	10 (15)	
Use of TKI, n (%)				0.449
No	118 (89)	60 (91)	58 (87)	
TKI I	9 (7)	4 (6)	5 (7)	
TKI II	1 (1)	1 (2)	0 (0)	
TKI III	5 (4)	1 (2)	4 (6)	
Use of VEGF inhibitor, n (%)				0.645
No	114 (86)	58 (88)	56 (84)	

Continued

Table 1 Continued

Variation	Total (n=133)	Cohort, median (IQR)		P value
		miR-219-5p <1.50 (n=66)	miR-219-5p ≥1.50 (n=67)	
Yes	19(14)	8 (12)	11(16)	
KPS score, n (%)				0.678
40	2 (2)	0 (0)	2 (3)	
50	5 (4)	3 (5)	2 (3)	
60	7 (5)	3 (5)	4 (6)	
70	12 (9)	8 (12)	4 (6)	
80	29 (22)	14 (21)	15 (22)	
90	56 (42)	29 (44)	27 (40)	
100	22 (17)	9 (14)	13 (19)	
Smoking, n (%)				0.255
No	51 (38)	29 (44)	22 (33)	
Yes	82 (62)	37 (56)	45 (67)	
Hypertension, n (%)				1
No	80 (60)	40 (61)	40 (60)	
Yes	53 (40)	26 (39)	27 (40)	
Diabetes, n (%)				1
No	116 (87)	58 (88)	58 (87)	
Yes	17 (13)	8 (12)	9 (13)	
Hyperlipaemia, n (%)				0.579
No	120 (90)	61 (92)	59 (88)	
Yes	13 (10)	5 (8)	8 (12)	
Heart failure, n (%)				1
No	130 (98)	65 (98)	65 (97)	
Yes	3 (2)	1 (2)	2 (3)	
ACS, n (%)				0.619
No	129 (97)	65 (98)	64 (96)	
Yes	4 (3)	1 (2)	3 (4)	

***P<0.001, **p<0.01, *p<0.05.
 ACS, acute coronary syndrome; AP, doxorubicin/cisplatin; BMI, body mass index; CEA, carcinoembryonic antigen; CRP, C reactive protein; DP, dipyridamole; EP, etoposide/cisplatin; GP, gemcitabine/cisplatin; KPS, Karnofsky Performance Status; NLR, neutrophil-lymphocyte ratio; PNI, prognostic nutritional index; SCLC, small cell lung cancer; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.

Development and validation of an OS prediction nomogram

The independently related risk factors derived from the multivariate analysis were used to create an OS estimation nomogram (figure 4A). The prognostic model was internally validated according to the bootstrap validation method. With an unadjusted C-index of 0.691 and a bootstrap-corrected C-index of 0.691, the nomogram displayed excellent accuracy in estimating the risk of OS. In the validation cohort, the nomogram showed a C-index of 0.691 for the estimation of OS. A suitable calibration curve for risk estimation was also displayed ($R^2=0.455$, likelihood-ratio $X^2=80.55$) (figure 4B). We collected 86 patients with NSCLC from Sichuan Cancer Hospital in the external validation step. The receiver operating characteristic curve showed an area under the curve (AUC) of

0.783 (0.743–0.822) for predicting 5-year OS, compared with an AUC of 0.749 (0.709–0.788) for the external validation data (figure 5). We calculated the total score using the nomogram for patients in the training and validation sets, respectively, and divided them into four groups (40–60, 61–80, 81–100, 101–120), and performed Kaplan-Meier analysis and plotted survival curves, which were found to have good separation and were statistically significant (online supplemental figure 1A,B).

DISCUSSION

In this study, we detected the expression of miR-219-5p in a large cohort of patients with SCLC at a single institution, between March 2010 and June 2015. The results

Table 2 Results of univariate Cox regression analysis for overall mortality

Variation	Non-adjustment		Model 1	
	HR (95% CI)	P value	HR (95% CI)	P value
Gender, male vs female	1.66 (1.02 to 2.69)	0.041*	–	–
Age (years), ≥60 vs <60	1.52 (1.03 to 2.26)	0.036*	–	–
BMI, ≥23.12 kg/m ² vs <22.86 kg/m ²	0.99 (0.69 to 1.43)	0.97	0.95 (0.66 to 1.38)	0.806
Serum CEA level, >3.43 ng/mL vs ≤3.43 ng/mL	1.01 (0.70 to 1.46)	0.954	1.00 (0.69 to 1.45)	0.999
Serum CRP level, >7.83 μmol/L vs ≤7.83 μmol/L	1.91 (1.31 to 2.78)	0.001**	1.92 (1.32 to 2.79)	0.001**
Albumin level, >39.46 g/L vs ≤39.46 g/L	1.66 (1.15 to 2.40)	0.007**	1.60 (1.10 to 2.31)	0.013*
Neutrophil count, >4.55×10 ⁹ /L vs ≤4.55×10 ⁹ /L	1.18 (0.82 to 1.71)	0.367	1.15 (0.79 to 1.66)	0.464
Lymphocyte count, >1.63×10 ⁹ /L vs ≤1.63×10 ⁹ /L	0.59 (0.40 to 0.85)	0.005**	0.61 (0.42 to 0.89)	0.01*
Haemoglobin level, >133 g/L vs ≤133 g/L	0.80 (0.56 to 1.16)	0.244	0.72 (0.49 to 1.05)	0.089
Platelet count, >233×10 ⁹ /L vs ≤233×10 ⁹ /L	1.23 (0.85 to 1.78)	0.275	1.23 (0.85 to 1.78)	0.275
PNI score, >47.9 vs ≤47.9	0.54 (0.37 to 0.78)	0.001**	0.53 (0.37 to 0.77)	0.001**
NLR, >2.66 vs ≤2.66	1.18 (0.82 to 1.71)	0.367	1.20 (0.83 to 1.74)	0.341
Metastasis, yes vs no	1.05 (0.70 to 1.57)	0.81	1.10 (0.73 to 1.64)	0.654
Stage of NSCLC, IV and III vs II and I	0.94 (0.50 to 1.75)	0.838	1.05 (0.56 to 1.98)	0.868
Stage of SCLC, yes vs no	1.33 (0.90 to 1.96)	0.154	1.43 (0.97 to 2.12)	0.074
Immunotherapy, yes vs no	0.28 (0.15 to 0.52)	<0.001***	0.30 (0.16 to 0.55)	<0.001***
Radiation therapy, yes vs no	0.88 (0.60 to 1.27)	0.488	0.79 (0.54 to 1.16)	0.235
Use of platinum, yes vs no	0.61 (0.15 to 2.47)	0.483	0.66 (0.16 to 2.70)	0.562
Target therapy, yes vs no	0.75 (0.42 to 1.33)	0.323	0.81 (0.45 to 1.45)	0.481
Use of TKI, yes vs no	0.77 (0.41 to 1.44)	0.415	0.82 (0.44 to 1.53)	0.534
Use of VEGF inhibitor, yes vs no	0.83 (0.47 to 1.45)	0.518	0.90 (0.51 to 1.59)	0.723
Chemotherapy, AP vs others	0.61 (0.37 to 1.00)	0.052	0.66 (0.40 to 1.09)	0.104
Smoking, yes vs no	1.23 (0.84 to 1.79)	0.292	0.90 (0.56 to 1.43)	0.645
Hypertension, yes vs no	1.13 (0.78 to 1.64)	0.531	1.10 (0.75 to 1.60)	0.622
Diabetes, yes vs no	0.90 (0.51 to 1.61)	0.726	0.97 (0.54 to 1.75)	0.927
Hyperlipaemia, yes vs no	0.79 (0.42 to 1.48)	0.461	0.77 (0.40 to 1.46)	0.421
Heart failure, yes vs no	5.61 (1.71 to 18.42)	0.004**	6.43 (1.94 to 21.26)	0.002**
ACS, yes vs no	0.74 (0.23 to 2.35)	0.612	0.69 (0.21 to 2.21)	0.53
KPS score, >80 vs ≤80	0.52 (0.35 to 0.75)	0.001**	0.51 (0.35 to 0.74)	<0.001***
miR-219-5p, ≥1.50 vs <1.50	0.36 (0.25 to 0.53)	<0.001***	0.37 (0.25 to 0.55)	<0.001***

Model 1: adjusted by age and gender.

***P<0.001, **p<0.01, *p<0.05.

ACS, acute coronary syndrome; AP, doxorubicin/cisplatin; BMI, body mass index; CEA, carcinoembryonic antigen; CRP, C reactive protein; KPS, Karnofsky Performance Status; NLR, neutrophil–lymphocyte ratio; NSCLC, non-small cell lung cancer; PNI, prognostic nutritional index; SCLC, small cell lung cancer; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.

suggested that reduced expression of miR-219-5p was significantly correlated with unfavourable clinical features. Moreover, patients in the group with high-level miR-219-5p expression displayed better OS compared with those in the group with low-level miR-219-5p expression. The multivariate analysis demonstrated miR-219-5p as an independent prognostic factor for OS. In addition, to propose, and retrospectively verify an independent cohort of patients, these independent risk factors were applied to establish a nomogram for OS estimation. The

nomogram revealed good accuracy in estimating the risk of OS.

Carcinogenesis involves multiple biological processes, which are related to many key genes.^{15 16} The characteristics of cancer occurrence represent properties that a cell acquires a certain ability to become and maintain itself as a cancer cell.¹⁷ The key genes guide the cellular signalling pathways related to occurrence and progression of cancers.^{18 19} Using miRNA expression to predict the clinical diagnosis and prognosis of cancer has more




Figure 2 Overall survival (OS) of patients with SCLC with different levels of miR-219-5p and different treatments. (A) OS of patients with SCLC with high or low level of miR-219-5p. (B) OS of patients with SCLC with different treatments (immunotherapy vs non-immunotherapy). SCLC, small cell lung cancer.

advantages than mRNAs, as miRNAs are proven to be the vital post-transcriptional regulators of gene expression.^{20 21} In comparison with mRNAs, these vital gene regulators are highly conserved among species.²²

It has been reported that miRNAs were related to the initiation and progression of various cancers, and many miRNAs have been identified as a promising biomarker for prognostic prediction of cancer.^{10 23} Recently, some miRNAs have been proven to be a novel prognostic biomarker for SCLC.^{24 25} A study by Yu *et al* indicated that miR-92a-2 was significantly higher in a group of patients with SCLC compared with a healthy control, and detection of miR-92a-2 levels could be a potential biomarker for patients with SCLC.²⁶ As a promising biomarker, miR-219-5p has been identified as a prognostic factor for different cancers. Long *et al* found that miR-219-5p expression level was distinctly decreased in melanoma tissues and cell lines, and the modulation of miR-219-5p

Figure 3




Figure 3 Multivariate Cox regression analysis of 5-year overall survival. CRP, C reactive protein; KPS, Karnofsky Performance Status; NLR, neutrophil-lymphocyte ratio; PNI, prognostic nutritional index.




Figure 4 Nomogram for overall survival (OS) risk estimation and its predictive performance. (A) Nomogram to estimate the OS risk of patients with SCLC. (B) Validity of the predictive performance of the nomogram in estimating the OS risk. LR, likelihood-ratio; SCLC, small cell lung cancer.

expression could be a prognostic biomarker and treatment strategy in melanoma.²⁷ A study from Huang *et al* suggested a role of miR-219-5p for prognostic prediction and therapeutic strategy in colorectal cancer.²⁸ However, there are no studies exploring the role of miR-219-5p as a biomarker in patients with SCLC. To the best of our knowledge, this study was the first attempt ever made to comprehensively evaluate the role of prognostic prediction based on miR-219-5p expression in patients with




Figure 5 External validation of the prognostic model. AUC, area under the curve.



SCLC. In the current study, we initially examined the expression levels of miR-219-5p in patients with SCLC. We, for the first time, demonstrated a correlation of the altered miR-219-5p expression with available clinical parameters. We found that miR-219-5p was significantly associated with lymphocyte count, PNI score and stage of SCLC. The univariate analysis indicated that increased miR-219-5p expression was a protective predictor for mortality. The Kaplan-Meier curve displayed that patients with elevated miR-219-5p expression levels or accepted immunotherapy had low cumulative incidence of death compared with those with reduced miR-219-5p expression or unaccepted immunotherapy, respectively. In addition, gender, age, serum CRP level, albumin level, lymphocyte count, PNI score, immunotherapy, heart failure, KPS score and miR-219-5p level were associated with overall mortality. The multivariate analysis showed that miR-219-5p, gender, PNI score, immunotherapy and heart failure could predict OS as the independent risk factors.

Nomograms are applied for visualisation of statistical models, graphical evaluation of variable significance and examination of predicted values.^{29–30} They have been widely used to predict cancer risks and therapeutic outcomes.^{31–32} Most recently, several studies have successfully established a prognostic nomogram that combined an miRNA with clinical-related variables for OS estimation in different cancers.^{33–35} Although a nomogram is becoming increasingly popular, no studies have built prognostic models using a combination of miR-219-5p and clinical risk factors in patients with SCLC. In this study, based on the combination of miR-219-5p and independent clinicopathological variables, we created a nomogram model that could provide an individual prognostic prediction for OS estimation in patients with SCLC. The results indicated excellent accuracy in estimating the risk of OS. There was a suitable calibration curve for risk estimation, indicating a well-performed nomogram, and good agreements between observation and prediction. To further verify the accuracy and efficiency of the model, an external data collection containing 86 patients from Sichuan Cancer Hospital was conducted. The results indicated that the prognostic model could accurately predict the prognosis of patients with SCLC. Hence, this was the first prognostic nomogram for patients with SCLC that considered clinical parameters in addition to miR-219-5p. This nomogram could provide comprehensive information for patients, as well as a better guidance for clinical therapy. Based on the model, the potential high-risk patients with low survival rate could be more accurately selected for a specific therapeutic strategy.

Strengths and limitations

We screened valid variables by Cox regression to construct a survival prediction model for SCLC and collected data for external validation in a logical manner. However, there are some limitations in this article. First, experimental research explaining the biological processes of

miR-219-5p is needed. Thus, the molecular mechanism of miR-219-5p should be investigated in further research. Second, the prognostic nomogram needs to be further assessed in a prospective and large-scale multicentre study before it can be applied to clinical practice. Finally, our data lacked some of the risk factors associated with SCLC for inclusion, such as the determination of some of the high-risk genes and the patient's previous chemotherapy and specific targeted therapies, which will require further analysis in our future studies.

CONCLUSIONS

In conclusion, we found that the miR-219-5p expression levels were significantly correlated with clinical parameters of patients with SCLC. Furthermore, miR-219-5p was proven to be an independent factor for prognostic prediction in patients with SCLC. Moreover, a nomogram based on multivariate analysis and including miR-219-5p expression levels showed excellent accuracy in estimating the risk of OS. However, a prospective validation of the prognostic nomogram will be needed in the future.

Author affiliations

¹Endocrinology, Suzhou Xiangcheng People's Hospital, Suzhou, Jiangsu, China

²Traumatology Surgery, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

³Medicine, Respiratory, Emergency and Intensive Care Medicine, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

⁴Medical Oncology, Medical School of University of Electronic Science and Technology of China, Chengdu, China

⁵General Surgery, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

⁶Urology, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, China

Contributors ZX, XW and ZC designed the study. ZC, XZ, JZ and MX collected and analysed the data. XW, ZC, JZ and XZ drafted the initial manuscript. ZX, XW and ZC reviewed and edited the article. ZX served as guarantor accepted full responsibility for the work and controlled the decision to publish. All authors read and approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Obtained.

Ethics approval For both the main cohort and the validation cohort, informed consent was obtained from all patients or their immediate family members for the collection and storage of samples and their use for future scientific research. All procedures were in line with the guidelines of the ethics committee of Suzhou Xiangcheng People's Hospital (20140193), Sichuan Cancer Hospital and the First Affiliated Hospital of Soochow University. The study was performed in accordance with the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines,

terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Zhijia Xu <http://orcid.org/0000-0002-1660-8534>

REFERENCES

- Torre LA, Bray F, Siegel RL, *et al*. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87–108.
- Gadgeel SM. Targeted therapy and immune therapy for small cell lung cancer. *Curr Treat Options Oncol* 2018;19:53.
- Abdel-Rahman O. Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: a secondary analysis of a phase III study. *Clin Respir J* 2018;12:2519–24.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70:7–30.
- Rafiei H, Ashrafizadeh M, Ahmadi Z. MicroRNAs as novel targets of sulforaphane in cancer therapy: the beginning of a new tale? *Phytother Res* 2020;34:721–8.
- Staicu CE, Predescu D-V, Rusu CM, *et al*. Role of microRNAs as clinical cancer biomarkers for ovarian cancer: a short overview. *Cells* 2020;9:169.
- Wang T, Du M, Zhang W, *et al*. MicroRNA-432 suppresses invasion and migration via E2F3 in nasopharyngeal carcinoma. *Oncol Targets Ther* 2019;12:11271–80.
- Van Meter EN, Onyango JA, Teske KA. A review of currently identified small molecule modulators of microRNA function. *Eur J Med Chem* 2020;188:112008.
- Liang Z, Feng A, Shim H. MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer. *Cancer Chemother Pharmacol* 2020;85:413–23.
- Condrat CE, Thompson DC, Barbu MG, *et al*. Mirnas as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. *Cells* 2020;9:276.
- Ma Q. MiR-219-5p suppresses cell proliferation and cell cycle progression in esophageal squamous cell carcinoma by targeting CCNA2. *Cell Mol Biol Lett* 2019;24:4.
- Gong T, Ning X, Deng Z, *et al*. Propofol-Induced mir-219-5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3-mediated Wnt/ β -catenin signalling activation. *J Cell Biochem* 2019;120:16934–45.
- Yang J, Sheng YY, Wei JW, *et al*. MicroRNA-219-5p promotes tumor growth and metastasis of hepatocellular carcinoma by regulating cadherin 1. *Biomed Res Int* 2018;2018:4793971.
- Wei C, Zhang X, He S, *et al*. MicroRNA-219-5p inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells by targeting the twist/wnt/ β -catenin signaling pathway. *Gene* 2017;637:25–32.
- Ashmore-Harris C, Fruhwirth GO. The clinical potential of gene editing as a tool to engineer cell-based therapeutics. *Clin Transl Med* 2020;9:15.
- Katase N, Nagano K, Fujita S. DKK3 expression and function in head and neck squamous cell carcinoma and other cancers. *J Oral Biosci* 2020;62:9–15.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646–74.
- Patel S, Alam A, Pant R, *et al*. Wnt signaling and its significance within the tumor microenvironment: novel therapeutic insights. *Front Immunol* 2019;10:2872.
- Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. *Mol Cancer* 2020;19:5.
- Lim LP, Lau NC, Garrett-Engele P, *et al*. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature* 2005;433:769–73.
- Mondal P, Natesh J, Kamal MA, *et al*. Non-Coding RNAs in lung cancer chemoresistance. *Curr Drug Metab* 2019;20:1023–32.
- Moss EG. MicroRNAs: hidden in the genome. *Curr Biol* 2002;12:R138–40.
- Pan YJ, Wan J, Wang CB. MiR-326: promising biomarker for cancer. *Cancer Manag Res* 2019;11:10411–8.
- Mao Y, Xue P, Li L, *et al*. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-gene pairs in small-cell lung cancer. *Mol Med Rep* 2019;20:2199–208.
- Uddin A, Chakraborty S. Role of miRNAs in lung cancer. *J Cell Physiol* 20, 2018.
- Yu Y, Zuo J, Tan Q, *et al*. Plasma mir-92a-2 as a biomarker for small cell lung cancer. *Cancer Biomark* 2017;18:319–27.
- Long J, Menggen Q, Wuren Q, *et al*. MiR-219-5p inhibits the growth and metastasis of malignant melanoma by targeting bcl-2. *Biomed Res Int* 2017;2017:9032502.
- Huang L-X, Hu C-Y, Jing L, *et al*. MicroRNA-219-5p inhibits epithelial-mesenchymal transition and metastasis of colorectal cancer by targeting lymphoid enhancer-binding factor 1. *Cancer Sci* 2017;108:1985–95.
- Iasonos A, Schrag D, Raj GV, *et al*. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol* 2008;26:1364–70.
- Balachandran VP, Gonen M, Smith JJ, *et al*. Nomograms in oncology: more than meets the eye. *Lancet Oncol* 2015;16:e173–80.
- Yang Y, Qu A, Zhao R, *et al*. Genome-Wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer. *Mol Oncol* 2018;12:2072–84.
- Kawai K, Ishihara S, Yamaguchi H, *et al*. Nomogram prediction of metachronous colorectal neoplasms in patients with colorectal cancer. *Ann Surg* 2015;261:926–32.
- Lv Y, Duanmu J, Fu X, *et al*. Identifying a new microRNA signature as a prognostic biomarker in colon cancer. *PLoS One* 2020;15:e0228575.
- Lai J, Chen B, Zhang G, *et al*. Identification of a novel microRNA recurrence-related signature and risk stratification system in breast cancer. *Aging (Albany NY)* 2019;11:7525–36.
- Zhang L, Chen J, Wang L, *et al*. Linc-PINT acted as a tumor suppressor by sponging miR-543 and miR-576-5p in esophageal cancer. *J Cell Biochem* 2019;120:19345–57.

Supplement Materials

Part I. Details of variants

Patients' age: The age of patients was based on the time of diagnosis of NSCLC.

Body mass index: The equation of body mass index (BMI) is calculated as follow: $BMI (kg/m^2) = weight (kg) / height (m)^2$. The data of BMI was recorded before clinical treatment.

Serum CEA level: The serum level of carcinoembryonic antigen (CEA) is one of tumor marks, the higher serum *CEA* level than that of healthy individuals led to its clinical application as a diagnostic biomarker for cancer.

Serum CRP level: C-reactive protein (CRP) is detected by colorimetric determination through fasting blood collection and CRP is one of the inflammation markers.

Albumin level: Serum albumin is detected by colorimetric determination through fasting blood collection. And serum albumin is one of the indicators of nutritional status.

Neutrophils count, lymphocytes count, hemoglobin level, platelet count: All these indexes were extracted from blood routine examination to evaluate preoperative status of patients.

PNI score: Prognostic nutritional index (PNI) is an index to evaluate the nutritional status of surgical patients, to predict the risk of surgery and to help make prognostic judgment. The equation is listed as below: $PNI = serum\ albumin (g/L) + 5 * lymphocytes (*10^9/L)$.

NLR: Neutrophil to Lymphocyte Ratio (NLR) is an index of inflammation markers to predict the prognosis of various cancer, including lung cancer.

Pathologic type: Non-small cell lung cancer can be classified as adenocarcinoma, squamous cell carcinoma, large cell lung cancer, or others, depending on surgical or tumor biopsy specimens

Stage of NSCLC: Non-small cell lung cancer was staged according to the seventh edition of international union against cancer (UICC) TNM was published in 2009

Surgery: For early and locally advanced NSCLC, which is generally acceptable, there is a history of surgical resection.

Therapy of radiation: Radiation therapy is a medical procedure that uses the delivery of high-energy radiation to kill cancer cells and shrink tumors, including external beam radiation therapy, internal radiation therapy and stereotactic body radiotherapy (SBRT). It aims to cure small tumors, treat lung cancer both locally and nearby lymph nodes, treat metastases, relieve symptoms, and also at prevention.

Application of platinum: Platinum-based chemotherapy may be used as a first or second line therapy for advanced lung cancer, after surgery (adjuvant chemotherapy), or before surgery to reduce the size of a tumor (neoadjuvant therapy). The most commonly used platinum drugs are cisplatin, carboplatin and nedaplatin. Treatment of non-small cell lung cancer begins with either cisplatin or carboplatin combined with another medication, such as docetaxel, pemetrexed, paclitaxel, gemcitabine and gemcitabine.

Target therapy: Targeted therapies for lung cancer are drugs that are tailored to attack certain mutations of cancer cells. These mutations lead to the production of abnormal proteins which guide the growth and development of a cancer cell. Common driver mutations include EGFR mutations, ALK rearrangements, ROS1 rearrangements, MET amplifications, KRAS mutations, HER2 mutations, BRAF mutations and so on.

Application of TKI: Tyrosine kinase inhibitors (TKI) act as competitive inhibitors of ATP binding to tyrosine kinases, or as tyrosine analogs that block tyrosine kinase activity and inhibit cell proliferation. Epithelial growth factor receptor (EGFR) is a protein that is present on the surface of both normal cells and lung cancer cells. Mutations in EGFR can occur at different locations on exon 18 to 21. ALK-positive lung cancer refers to people who have lung cancer that tests positive for the EML4-ALK fusion mutation. Several FDA-approved medications available to treat EGFR-positive and ALK-positive lung adenocarcinoma, including:

- EGFR inhibitors - Tarceva (erlotinib), Gilotrif (afatinib), Iressa (gefitinib), Tagrisso (osimertinib), and Portrazza (necitumumab)
- ALK inhibitors - Xalkori (crizotinib), Zykadia (ceritinib), and Alecensa (alectinib)
- ROS1 inhibitor - Xalkori (crizotinib)

Application of VEGF inhibitor: VEGF (Vascular endothelial growth factor) can activate angiogenesis through different signaling pathways. VEGF inhibitors are drugs that block the ability of tumors to form new blood vessels, and hence, grow and spread. Some currently available medications include bevacizumab, ramucirumab, axitinib, endostar and anlotinib.

KPS score: A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the

prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy. Patients with more than 80 scores had better postoperative status and longer survival time. And patients with more than 70 scores can suffer from chemoradiotherapy.

Smoking: Smoker refers to continuous or cumulative smoking > 1 cigarette/day over a lifetime of more than 6 months. (1997, WHO)

Hypertension: Hypertension is defined as a repeatedly elevated blood pressure exceeding 140 over 90 mmHg.

Diabetes: Diabetes is a group of metabolic diseases characterized by hyperglycemia. And fasting blood glucose more than 7.0 mmol/l or blood glucose more than 11.1 mmol/l within 2 hours after meal can be diagnosed diabetes.

Hyperlipemia: Hyperlipemia means the presence of excess fat or lipids in the blood. And total cholesterol ≥ 6.2 mmol/L, low density lipoprotein cholesterol ≥ 4.1 mmol/L, triglyceride ≥ 2.3 mmol/L, high density lipoprotein cholesterol < 1.0 mmol/L can be diagnosed hyperlipemia.

Heart failure: The information was recorded through history taking and verified after hospitalization. Heart failure means inability of the heart to keep up with the demands on it and, specifically, failure of the heart to pump blood with normal efficiency. Heart failure may be due to failure of the right or left or both ventricles. The signs and symptoms depend upon which side of the heart is failing. They can include shortness of breath (dyspnea), asthma due to the heart (cardiac asthma), pooling of blood (stasis) in the general body (systemic) circulation or in the liver's (portal) circulation, swelling (edema), blueness or duskiess (cyanosis), and enlargement (hypertrophy) of the heart.

ACS: Acute coronary syndrome is a term for a group of conditions that suddenly stop or severely reduce blood from flowing to the heart. When blood cannot flow to the heart, the heart muscle can become damaged. Heart attack and unstable angina are both acute coronary syndromes (ACS).

Withdraw treatment: Reasons for patients withdrew from treatment were listed below: 1) High cost of the treatment: In China, the cost of hormone therapy can be up to 3000 RMB a month if without health insurance. 2) Poor patient compliance: Some patients discontinue treatment because they do not comply with the treatment plan prescribed by their doctor.

Part II. Report of sample size assessment

PASS 15.0.5

1

Tests for Two Survival Curves Using Cox's Proportional Hazards Model

Numeric Results with Ha: HR ≠ 1

	Total Sample Size	Control Sample Size	Trtmnt Sample Size	Prop'n Control N1/N	Hazard Ratio h2/h1	Control Prob Event Pev1	Trtmnt Prob Event Pev2	Control Events E1	Trtmnt Events E2	Alpha	Beta
Power	N	N1	N2	P1	HR						
0.9005	103	51	52	0.500	0.500	0.750	0.950	38.3	49.4	0.050	0.100

References

- Chow, S.C., Shao, J., Wang, H. 2008. Sample Size Calculations in Clinical Research, 2nd Edition. Chapman & Hall/CRC.
- Schoenfeld, David A. 1983. 'Sample Size Formula for the Proportional-Hazards Regression Model', Biometrics, Volume 39, Pages 499-503.

Report Definitions

Power is the probability of rejecting a false null hypothesis. Power should be close to one.

N is the total sample size.

N1 and N2 are the sample sizes of the control and treatment groups.

P1 is the proportion of the total sample that is in the control group, group 1.

HR is the hazard ratio: h2/h1.

Pev1 and Pev2 are the probabilities of an event in the control and the treatment groups.

E1 and E2 are the number of events required in the control and the treatment groups.

Alpha is the probability of a type one error: rejecting a true null hypothesis.

Beta is the probability of a type two error: failing to reject a false null hypothesis.

Summary Statements

A two-sided test of whether the hazard ratio is one with an overall sample size of 103 subjects (of which 51 are in the control group and 52 are in the treatment group) achieves 90% power at a 0.050 significance level when the hazard ratio is actually 0.500. The number of events required to achieve this power is 87.7. It is anticipated that proportions of subjects having the event during the study is 0.750 for the control group and 0.950 for the treatment group. These results assume that the hazard ratio is constant throughout the study and that Cox proportional hazards regression is used to analyze the data.

Procedure Input Settings

Autosaved Template File

\\Mac\Home\Documents\PASS 15\Procedure Templates\Autosave\Tests for Two Survival Curves Using Cox's

Proportional Hazards Model - Autosaved 2020_1_24-9_57_39.t92

Design Tab

Solve For:	Sample Size
Alternative Hypothesis:	Ha: HR \neq 1
Power:	0.90
Alpha:	0.05
Group Allocation:	Equal (N1 = N2)
Pev1 (Probability of a Control Event):	0.750
Pev2 (Probability of a Treatment Event):	0.950
HR (Actual Hazard Ratio = h2/h1):	0.5

Figure S1a




Figure S1b

